Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: A review

Journal of Clinical Oncology

Volumn 20, Issue 8, 2002, Pages 2197-2207

  Berinstein, Neil L ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ALVAC; ANTIIDIOTYPIC ANTIBODY; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CEAVAC; EPITOPE; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA B7 ANTIGEN; HLA B7.1 ANTIGEN; KEYHOLE LIMPET HEMOCYANIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; QS 21; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN FUNCTION; ANTIGEN STRUCTURE; CANCER; CANCER CELL CULTURE; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; DRUG RESPONSE; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE SUBPOPULATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ANIMALS; ANTIBODY FORMATION; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CLINICAL TRIALS; EPITOPES; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTE SUBSETS; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASMS; POXVIRIDAE;

EID: 0037089660     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.08.017     Document Type: Review

References (72)

1. The cell biology of antigen presentation in dendritic cells
2. CD28-B7 interactions in T cell activation
3. Tumour immunotherapy: New tools, new treatment modalities and new T-cell antigens
4. Stuck in the MUC: On the long and winding road
5. Treatment of lymphoid tumours with anti-idiotype antibodies
6. Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: Characterization and use as probes for the biology of the tumour in vivo and in vitro
7. IDED C2B8 anti-CD20 antibody: Final report on a phase III pivotal trial in patients with relapsed low grade or follicular lymphoma
8. Trastuzumab and breast cancer
9. Efficient tumour eradication by adoptively transferred cytotoxic T cell clones in allogenic hosts
10. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
11. Recognition of multiple epitopes in the human melanoma antigen gpl00 by tumour-infiltrating T lymphocytes associated with in vivo tumour regression
12. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
13. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
14. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
15. Cancer immunotherapy: Synthetic and natural peptides in the balance
16. The central role of CD4(+) t cells in the antitumor immune response
17. The role of MHC class II-restricted: Tumour antigens and CD4+T cells in antitumor immunity
18. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity
19. Importance of CD4(+) T helper cell responses in tumor immunity
20. Assays for monitoring cellular immune responses to active immunotherapy of cancer
21. Reverse ELISPOT assay for clonal analysis of cytokine production: I. Enumeration of gamma interferon-secreting cells
22. Quantification of tumor-specific T lymphocytes with the ELISPOT assay
23. Immunologic monitoring of clinical trials in patients with cancer technology versus common sense
24. Quantification of antigen specific CD8+ T cells using an ELISPOT assay
25. Digital quantification of the enzyme-linked immunospot (ELISPOT)
26. Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine
27. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
28. Melanoma vaccines: The paradox of T cell activation without clinical response
29. Tumour regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A 1
30. Eradication of established tumors by CD8+ T cell adoptive immunotherapy
31. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells
32. Association between CEA-specific T cell responses (TCR) following treatment with Vaccinia CEA (V) and Alvac CEA (A) and survival in patients with CEA bearing cancers
33. The carcinoembryonic antigen (CEA): Past, present, and future
34. Carcinoembryonic antigen, a human tumour marker, functions as an intercellular adhesion molecule
35. Carcinoembryonic antigen, a human tumour marker, cooperates with Myc and Bcl-2 in cellular transformation
36. The specificity for the differentiation blocking activity of carcinoembryonic antigen resides in its glycophosphatidylinositol anchor
37. Self recognition in the Ig superfamily: Identification of precise subdomains in carcinoembryonic antigen required for intercellular adhesion
38. Human carcinoembryonic antigen functions as a general inhibitor of anoikis
39. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
40. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen
41. Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA)
42. Identification of an enhancer agonist cytotoxic Y lymphocyte peptide from human carcinoembryonic antigen
43. The multi-epitope approach for immunotherapy for cancer: Identification of several CTL epitopes form various tumor-associated antigens expressed on solid epithelial tumors
44. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine
45. The use of Epstein-Barr virus-transformed B lymphocyte cell lines in a peptidereconstitution assay: Identification of CEA-related HLA-A*0301-restricted potential cytotoxic T-lymphocyte epitopes
46. Identification of HLA-A3-restricted cytotoxic T lymphocyte eptiopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells
47. In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells
48. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumour-reactive cytotoxic T lymphocyte
49. Identification of new epitopes form four different tumor-associated antigens: Recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity
50. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide
51. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach
52. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-I)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
53. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumour immunotherapy
54. Pharmacological administration of granulocyte/macrophage-colony-stimulation factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen
55. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen
56. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen
57. Applications of poxvirus vectors to vaccination: An update
58. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein
59. Efficacy studies on a canarypox rabies recombinant virus
60. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses
61. Induction of protective host immunity to carcinoembryonic antigen (CEA) a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus
62. Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccinia
63. Phase I study in cancer patients of a replication-defective avipox recominbant vaccine that expresses human carcinoembryonic antigen
64. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses
65. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas
66. Phase I Study of Vaccine Therapy with ALVAC-CEA B7.1 and GM-CSF (G) in Patients (PTS) with Advanced CEA-Expressing Cancers
67. The Influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma
68. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule
69. Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial
70. Complete molecular remissions induced by patient-specific vaccination plus granulocytemonocyte colony-stimulating factor against lymphoma
71. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: Long term results of a clinical trial
72. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines